Four Federal Efforts to Monitor, Including RESULTS Act Progress
Other proposals aim to increase fraud enforcement, temper prior authorization, and modernize CLIA
Other proposals aim to increase fraud enforcement, temper prior authorization, and modernize CLIA
A federal appeals court upheld the idea that clinical laboratories can rely on physician orders to justify medical necessity
Genetic testing now accounts for 43 percent of all Medicare Part B laboratory spending
Research into independent medical review data in four states show payers’ internal policies affect rates of overturns
Cuts to reimbursement rates under PAMA have been pushed back again by Congress, this time to January 2027
However, attorney Danielle Sloane urges labs to be proactive about potential PAMA reporting requirements on Jan. 31 if the bill doesn’t pass quickly
Better clinical laboratory test data reporting would allow ‘Medicare rates to be more appropriately set,’ says Susan Van Meter
Bill that ended government shutdown includes provision to hold off PAMA cuts
How clinical laboratories should prepare for the next wave of oversight in the new year
However, a proposed bill called the RESULTS Act is racing to thwart the cuts to lab test reimbursement rates
Government reform and payer streamlining may reduce the burden on healthcare providers, but laboratories should remain vigilant